Publication

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.

Journal Paper/Review - Nov 10, 2022

Units
PubMed
Doi
Contact

Citation
Smolen J, Landewé R, Bergstra S, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards C, Hyrich K, Pope J, de Souza S, Stamm T, Takeuchi T, Verschueren P, Winthrop K, Balsa A, Bathon J, Buch M, Burmester G, Buttgereit F, Cardiel M, Chatzidionysiou K, Codreanu C, Cutolo M, den Broeder A, El Aoufy K, Finckh A, Fonseca J, Gottenberg J, Haavardsholm E, Iagnocco A, Lauper K, Li Z, McInnes I, Mysler E, Nash P, Poór G, Ristic G, Rivellese F, Rubbert-Roth A, Schulze-Koops H, Stoilov N, Strangfeld A, van der Helm-van Mil A, van Duuren E, Vliet Vlieland T, Westhovens R, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2022
Type
Journal Paper/Review (English)
Journal
Ann Rheum Dis 2022
Publication Date
Nov 10, 2022
Issn Electronic
1468-2060
Brief description/objective

To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing the most recent developments in the field.